Location: Brussels, Belgium
Closing Date: 09 Feb 17
Salary (£): Competitive
Do you know Covance is one of the most stable, fastest growing global Contract Research Organization? For example, we have supported the development of one-third of all prescription medicines in the market today and of 100 % out of the 50 best-selling drugs. The work we do at Covance impact the lives of millions of people around the world…
CRA vacancies Covance Belgium Min. 2 years Experience in ph I-III trials, mainly Oncology.
We are currently seeking to hire Clinical Research Associates.
This is a permanent position based in Brussels office or home based in Belgium.
To be successful in this position, you will need to be educated to degree level in life science or/and paramedical science area. Additionally, you will need to demonstrate:
The opportunity to pursue further training and an interesting career in an inspiring environment that values achievement, supports a balance between your personal and professional life and allows you to make meaningful contributions. Covance's ongoing success offers team members unsurpassed growth and career development opportunities.
At Covance, we help make the miracles of medicine a reality. We offer opportunities to work on diverse, challenging projects with bright, interesting colleagues while building a flexible and rewarding career. This is your chance to become part of a team that helps to bring miracle of medicine to market sooner.
There is no better time to join us!
Covance is committed to diversity in the workplace and is an equal opportunity employer (Minority/Female/Individual with Disability/Veteran). Your confidentiality and privacy are important to us.
|Website:||Visit Our Web Site|
PharmiWeb.com is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on PharmiWeb.com is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.